TERN Projected Dividend Yield
Terns Pharmaceuticals Inc ( NASDAQ : TERN )Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Co.'s primary program is TERN-101, a liver-distributed, non-bile acid Farnesoid X Receptor (FXR) agonist that has demonstrated sustained liver FXR activation, as well as a favorable tolerability profile across multiple clinical trials. Co.'s another clinical stage program, TERN-201, is an inhibitor of Vascular Adhesion Protein-1. Co. is also evaluating the potential to co-administer TERN-201 in combination with a metabolically active NASH treatment. 20 YEAR PERFORMANCE RESULTS |
TERN Dividend History Detail TERN Dividend News TERN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |